Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN – Research Report), Sarepta Therapeutics (SRPT – Research Report) and Karuna Therapeutics (KRTX – Research Report).
Amgen (AMGN)
In a report released today, Steve Chesney from Atlantic Equities maintained a Sell rating on Amgen, with a price target of $182.00. The company’s shares closed last Monday at $247.29.
According to TipRanks.com, Chesney is a 2-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Amgen with a $241.92 average price target, a -1.3% downside from current levels. In a report issued on July 28, Robert W. Baird also maintained a Sell rating on the stock with a $185.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Sarepta Therapeutics (SRPT)
In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Sarepta Therapeutics, with a price target of $182.00. The company’s shares closed last Monday at $111.47, close to its 52-week high of $111.90.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of
Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $131.00, representing a 23.6% upside. In a report issued on July 25, SVB Securities also maintained a Buy rating on the stock with a $126.00 price target.
Karuna Therapeutics (KRTX)
SVB Securities analyst Marc Goodman maintained a Buy rating on Karuna Therapeutics today and set a price target of $270.00. The company’s shares closed last Monday at $241.19, close to its 52-week high of $245.00.
According to TipRanks.com, Goodman is a 3-star analyst with an average return of
Karuna Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $225.58, representing a 2.1% upside. In a report released yesterday, Citigroup also maintained a Buy rating on the stock with a $280.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMGN:
